Freddy Van Goethem

Freddy Van Goethem

Auto-generated profile, based on publicly available information

Freddy Van Goethem

Vrije Universiteit Brussel, Department of In Vitro Toxicology and Dermato-Cosmetology

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
SSSara Sepehri
Sara Sepehri
DWDinja De Win
Dinja De Win
AHAnja Heymans
Anja Heymans
FGFreddy Van Goethem
Freddy Van Goethem
RRRobim M Rodrigues
Robim M Rodrigues
TVTamara Vanhaecke
Tamara Vanhaecke
This study employs animal-free Next Generation Risk Assessment (NGRA) principles to evaluate the safety of repeated dermal exposure to 2.5% (w/w) HC Yellow No. 13 (HCY13) hair dye. As multiple in silico tools consistently flagged hepatotoxic potential, likely due to HCY13's trifluoromethyl group, which is known to interfere with hepatic lipid metabolism, liver steatosis was chosen as the primary mode of action for evaluation. AOP-guided in vitro tests were conducted, exposing human stem cell-derived hepatic cells to varying HCY13 concentrations over 72 h. The expression of 11 lipid metabolism-related marker genes (AHR, PPARA, LXRA, APOB, ACOX1, CPT1A, FASN, SCD1, DGAT2, CD36, and PPARG) and triglyceride accumulation, a phenotypic hallmark of steatosis, were measured. PROAST software was used to calculate in vitro Points of Departure (PoDNAM) for each biomarker. Using GastroPlus 9.9, physiologically-based pharmacokinetic (PBPK) models estimated internal liver concentrations (Cmax liver) of HCY13, ranging from 4 to 20 pM. All PoDNAM values significantly exceeded the predicted Cmax liver, indicating that HCY13 at 2.5% (w/w) is unlikely to induce liver steatosis under the assumed conditions. This research demonstrates the utility of NGRA, integrating AOP-based in vitro assays and computational models to protect human health and support regulatory decision-making without animal testing.

11 August 2025 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
EDE. Demuynck
E. Demuynck
TVT. Vanhaecke
T. Vanhaecke
ATA. Thienpont
A. Thienpont
DCDavie Cappoen
Davie Cappoen
FGF. Van Goethem
F. Van Goethem
BMBirgit Mertens
Birgit Mertens

25 April 2025 in Toxicology
Verified
Journal Article
Open access
ATAnouck Thienpont
Anouck Thienpont
ECEunnara Cho
Eunnara Cho
AWAndrew Williams
Andrew Williams
MMMatthew J. Meier
Matthew J. Meier
CYCarole L. Yauk
Carole L. Yauk
BMBirgit Mertens
Birgit Mertens
In vitro transcriptomics holds promise for high-throughput, human-relevant data but is not yet integrated into regulatory decision-making due to the lack of standardized approaches. For genotoxicity assessment, transcriptomic biomarkers such as GENOMARK and TGx-DDI facilitate qualitative and quantitative analysis of complex in vitro transcriptomic datasets. However, advancing their use in quantitative testing requires standardized methods for deriving transcriptomic Points of Departure (tPoDs) and linking them to in vivo responses. Herein, we investigated different approaches to calculate tPoDs and applied in vitro to in vivo extrapolation to obtain administered equivalent doses (AEDs). Human HepaRG cells were exposed for 72 h to 10 known in vivo genotoxicants (glycidol, methyl methanesulfonate, nitrosodimethylamine, 4-nitroquinoline-N-oxide, aflatoxin B1, colchicine, cyclophosphamide, mitomycin C, ethyl methanesulfonate, and N-Nitroso-N-ethylurea) from the highest concentration that induces up to 50 % cytotoxicity through a range of lower concentrations. Gene expression data was generated using a customized version of the TempO-Seq® human S1500 + gene panel. The GENOMARK and TGx-DDI biomarkers produced genotoxic calls for all of these reference genotoxicants. Next, we performed benchmark concentration (BMC) modeling to generate both genotoxicity-specific biomarker (tPoDbiomarkers) and generic tPoDs (tPoD S1500+). High-throughput toxicokinetic models estimated the human AEDs for these tPoDs, which were compared with (a) previously reported genotoxicity-specific AEDs from other New Approach Methodologies, and (b) in vivo PoDs from animal studies. We found that the generic AEDs were more conservative than genotoxicity-specific biomarker AEDs. For six of the nine genotoxicants, transcriptomic AEDs were lower than the in vivo PoDs; refined kinetic models may improve predictions. Overall, in vitro transcriptomic data in HepaRG cells provide protective estimates of in vivo genotoxic concentrations, consistent with other in vitro genotoxicity testing systems.

17 March 2025 in Toxicology
Verified
Journal Article
Closed access
ADAnnika Drees
Annika Drees
VNVahid Nassiri
Vahid Nassiri
ATAndrés Tabernila
Andrés Tabernila
JSJan Serroyen
Jan Serroyen
EGEmmanuel Gustin
Emmanuel Gustin
JSJulen Sanz-Serrano
Julen Sanz-Serrano

13 July 2026 in Life Sciences
Verified
Journal Article
Open access
AGAlexandra Gatzios
Alexandra Gatzios
MSMarth Stinckens
Marth Stinckens
AVAnouk Verhoeven
Anouk Verhoeven
MRMatthias Rombaut
Matthias Rombaut
DWDinja De Win
Dinja De Win
TVTamara Vanhaecke
Tamara Vanhaecke
Several genetic variants have been identified that impact outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH), but cellular platforms to identify molecular targets for treatment remain scarce. This study aims to employ a polygenic risk score for hepatic fat content (PRS-HFC) in a human-based in vitro model to identify potential druggable targets related to a genetic risk for MASH. Ninety-two human skin-derived precursor (hSKP) cell lines were genotyped and classified according to their PRS-HFC. Per risk category, five cell lines were selected and differentiated to hepatic progenitor-like cells (hSKP-HPCs) before being exposed to MASH-related triggers or control medium. Lipid accumulation, fatty acid uptake, generation of oxidative stress, secretion of inflammatory mediators, and alterations of the transcriptome were assessed. Potential drug targets were modulated using siRNA. hSKP-HPCs displayed a positive correlation between lipid accumulation and PRS-HFC, both in the control and 'MASH' condition. hSKP-HPCs with high PRS-HFC exhibited increased secretion of interleukin 6 and enhanced fatty acid uptake. Bulk RNA barcoding and sequencing revealed distinct gene expression profiles depending on genetic predisposition and predicted increased CD36-signalling as potential upstream regulator thereof. Silencing of CD36 effectively reduced lipid accumulation in cultures with high PRS-HFC and attenuated expression of genes related to de novo lipogenesis, lipolysis and inflammation. hSKP-HPCs recapitulate the effect of the PRS-HFC on lipid accumulation and inflammation. CD36 appeared to at least partially mediate these effects, and its silencing further substantiated its role in conferring high genetic risk for MASH, highlighting CD36 as a potential therapeutic target for genetically-driven MASH. ABBREVIATIONS.

13 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LWLevi M.T. Winkelman
Levi M.T. Winkelman
EDEmmanuel Demuynck
Emmanuel Demuynck
SBSteven M. Bryce
Steven M. Bryce
MSMaciej Stepnik
Maciej Stepnik
ATAnouck I. Thienpont
Anouck I. Thienpont
JBJoost Beltman
Joost Beltman
Quantitative Adverse Outcome Pathways (qAOPs) help translate mechanistic knowledge into quantitative toxicity predictions; however, their development is constrained by the limited availability and heterogeneity of quantitative data. Here, we investigated the feasibility of developing a qAOP for genotoxicity by modeling quantitative relationships linking DNA alkylation to increased mutations and structural chromosome aberrations through intermediate biological key events (KEs). We compiled and harmonized published concentration-response data from human lymphoblastoid TK6 cells exposed to ethyl methanesulfonate, methyl methanesulfonate, or N-ethyl-N-nitrosourea, covering eight genotoxicity assays representing five KEs with well-established dependencies. We evaluated sources of variability, compared points of departure (PoDs), and quantified relationships between successive events using response-response modeling. Substantial between-study variability could to a limited extent be explained through differences in experimental design while batch effects for individual studies and researchers were substantial. PoD estimates that were calculated from combined results of independent studies with similar experimental design, were often uncertain due to insufficient concentration-response characterization or conflicting results between studies. Nevertheless, response-response modeling suggested a threshold effect for certain key-event relationships (KERs). Specifically, DNA adducts seemed to be triggered at lower concentrations of alkylating agents compared to the subsequent KEs of DNA strand breaks and chromosome aberrations. Furthermore, these fitted response-response models can be used for prediction of downstream KEs from earlier ones. The general approach we developed for BMC analysis followed by response-response modeling is applicable to other AOPs as well. These findings highlight both the feasibility and limitations of using existing data for qAOP development.